Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $1.0 million.

  • CytomX Therapeutics' Other Non-Current Assets rose 9.74% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 9.74%. This contributed to the annual value of $1.0 million for FY2024, which is 1199.56% up from last year.
  • As of Q3 2025, CytomX Therapeutics' Other Non-Current Assets stood at $1.0 million, which was up 9.74% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Other Non-Current Assets ranged from a high of $1.0 million in Q1 2025 and a low of $917000.0 during Q1 2021
  • Its 5-year average for Other Non-Current Assets is $946105.3, with a median of $917000.0 in 2021.
  • As far as peak fluctuations go, CytomX Therapeutics' Other Non-Current Assets tumbled by 5778.08% in 2021, and later soared by 1210.47% in 2025.
  • CytomX Therapeutics' Other Non-Current Assets (Quarter) stood at $917000.0 in 2021, then changed by 0.0% to $917000.0 in 2022, then changed by 0.0% to $917000.0 in 2023, then rose by 12.0% to $1.0 million in 2024, then grew by 0.1% to $1.0 million in 2025.
  • Its Other Non-Current Assets was $1.0 million in Q3 2025, compared to $1.0 million in Q2 2025 and $1.0 million in Q1 2025.